Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with the report dated February 17, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions executed by company executives.
| Transaction Type | Instrument | Price | Total Volume |
|---|---|---|---|
| Sale for Tax Liabilities | American Depositary Shares (ADSs) | $35.6978 | 159,796 |
| Sale for Tax Liabilities | Ordinary Shares (GBP) | £12.6107 | 227,717 |
| Cash Settlement | Ordinary Shares (GBP) | £12.6107 | 9,181 (Equivalent Value) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine transactions where executives sold shares or received cash settlements to meet tax liabilities arising from the vesting of awards granted in 2018 under the Company's 2017 Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a compliance disclosure of specific share transactions executed on February 12 and February 15, 2021, on the New York Stock Exchange (XNYS) and London Stock Exchange (XLON).
Investor Verification Points
- Verify that the reported share sales were executed strictly to meet tax withholding obligations for vesting awards, rather than discretionary trading.
- Confirm the consistency of the transaction prices ($35.6978 for ADSs and £12.6107 for Ordinary Shares) with the market closing prices on February 12, 2021.
- Review the 2017 Performance Share Plan terms to understand the vesting schedule and tax implications for the 2018 grants referenced.
- Note that one executive (Ms. D. Conrad) received a cash settlement equivalent to the market value of shares rather than a direct share sale.